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USPHS/IDSA Guidelines for the Prevention of
Opportunistic Infections in Persons Infected with
Human Immunodeficiency Virus: A Summary
PREFACE
In the United States, opportunistic infections reduce the quality and duration of life
for approximately 1 million persons who have HIV infection (1 ), especially for the
estimated 250,000 persons who are severely immunosuppressed, as measured by a
CD4+ T-lymphocyte count below 200 cells/µL (2 ; CDC, unpublished data). In the late
1980s and early 1990s, efforts to prevent opportunistic infections focused first on
chemoprophylaxis against Pneumocystis carinii pneumonia (PCP) (3,4 ), and then on
chemoprophylaxis against disseminated Mycobacterium avium complex (MAC) dis-
ease (5 ).
During the past decade, clinicians and researchers have learned that, in addition to
P. carinii and MAC, other pathogens can cause disease in patients with HIV infection.
Knowledge regarding the reduction of risk of exposure to, and thus acquisition of,
opportunistic pathogens also has increased. During this decade, the number of
chemoprophylactic regimens available for preventing disease also has increased. In-
formation about preventing exposure and preventing disease is often published in
journals that are not regularly reviewed by health-care providers; some of it has not
yet been published.
In 1994, the U.S Public Health Service (USPHS)—-primarily through the efforts of
CDC and the National Institutes of Health (NIH) and the Infectious Diseases Society of
America (IDSA)—-recognized the importance of preventing oportunistic infections
and the need to consolidate information for health-care providers. In response, these
organizations initiated an effort to develop comprehensive recommendations for the
prevention of opportunistic infections in HIV-infected persons. Draft recommenda-
tions were reviewed by consultants from CDC, NIH, and IDSA, as well as by members
of other Federal and non-Federal agencies, community organizations, physicians
caring for HIV-infected persons, and HIV-infected persons themselves. These recom-
mendations were discussed at a 2-day meeting convened by CDC, NIH, and IDSA in
Atlanta in September 1994. Comments were solicited from the public, and final rec-
ommendations were approved by USPHS and IDSA. These recommendations were
also endorsed by the American Academy of Pediatrics, the Infectious Diseases Society
of Obstetrics and Gynecology, and the Society of Healthcare Epidemiologists of Amer-
ica. The recommendations are designed for the use of health-care providers, but they
also can provide useful information for HIV-infected patients.
The full text of the USPHS/IDSA Guidelines for the Prevention of Opportunistic In-
fections in Persons Infected with Human Immunodeficiency Virus is being published
in a supplement to Clinical Infectious Diseases (6–8 ). This report excerpts the disease-
specific recommendations that form the basis for the guidelines. These recom-
mendations address 17 opportunistic infections or groups of opportunistic infections
by providing guidelines on a) preventing exposure to the opportunistic pathogens,
b) preventing the first episode of disease (by chemoprophylaxis or vaccination), and
c) preventing disease recurrence (by long-term maintenance drug therapy). This
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report also includes the drug regimens used to prevent opportunistic infections in HIV-
infected adults and adolescents and infants and children.
Several factors were considered in developing these recommendations, including
a) the level of immunosuppression at which opportunistic disease is most likely to
occur; b) the incidence of disease; c) the severity of disease in terms of morbidity, cost
of care (including hospitalization), and mortality; d) the feasibility, efficacy, and cost of
the prevention measure; e) the impact of the prevention measure on the quality of life;
and f) (for chemoprophylaxis recommendations) drug toxicities, drug interactions,
and the potential for the development of drug resistance. 
Recommendations are rated according to the strength of the recommendation for
or against use (letters A–E) and the quality of the evidence supporting the recommen-
dation (Roman numerals I–III) (6 ) (Tables 1,2). When applying the letter ratings A–E to
recommendations involving chemoprophylaxis, the strength of evidence and magni-
tude of clinical benefit were balanced against the toxicity, drug interactions, and cost
of the chemoprophylactic regimen and the feasibility of alternative approaches such
as early diagnosis and treatment of the opportunistic infection. Recommendations
designated “A” are supported by evidence that is both statistically and clinically per-
suasive, are strongly recommended, should always be offered, and are considered
standard care. Those designated “B” are recommended for consideration; such meas-
ures should generally be offered but should involve some discussion of the pros and
cons between the provider and the patient. Measures designated “C” are considered
optional, either because evidence of benefit is insufficient or because any proven
benefit is minimal from the clinical standpoint and may not outweigh either the toxic-
ity, drug interactions, or cost of the chemoprophylaxis or the feasibility of alternative
approaches. Measures designated “D” should generally not be offered; those desig-
nated “E” are contraindicated. The Roman numeral ratings I–III refer to the quality of
evidence that forms the basis for the recommendations regarding the use of a product
or measure for preventing opportunistic infections in HIV-infected persons.
Applying this rating system to recommendations regarding prevention of exposure
was complicated by the lack of information regarding the effectiveness of various
counseling messages. Therefore, few “prevention of exposure” recommendations
are rated “A”; many are considered optional (rating “C”). However, use of the rating
system should facilitate understanding of the relative importance of the various pre-
vention recommendations.  
The prevention recommendations presented here differ from those previously pub-
lished because they include strategies for preventing many opportunistic infections
not previously discussed, particularly those associated with prevention of exposure.
They also modify earlier recommendations. For example, for PCP prophylaxis for
sulfa-intolerant patients, either dapsone or dapsone plus pyrimethamine are now rec-
ommended in preference to aerosolized pentamidine. For prophylaxis against initial
episodes of disseminated MAC disease, the threshold of treatment has been lowered
from 100 to 75 CD4+ T-lymphocytes/µL. Chemoprophylaxis against toxoplasmic en-
cephalitis is now recommended. 
In this report, the disease-specific recommendations are not listed in priority order.
Health-care providers who manage and treat  HIV-infected patients should consult the
overview of the USPHS/IDSA guidelines, which addresses both the initial and follow-
up evaluations of the HIV-infected patient (7 ). In addition to opportunistic infections
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addressed in the disease-specific recommendations, the overview of the guidelines
briefly addresses other infections that occur with increased frequency in HIV-infected
persons (e.g., syphilis, hepatitis B, and other sexually transmitted diseases). Sections
on preventing opportunistic infections in children and in pregnant women are in-
cluded. In this report, only the tables concerning drugs and doses in adults and
children (Tables 3a, 3b and 4a, 4b) and the summary of prevention of exposure recom-
mendations (Table 5) have been excerpted from the overview. The approach to
preventing opportunistic infections and other infections commonly encountered in
HIV-infected persons, as described in the overview, should be integrated with other
aspects of HIV care, as described elsewhere (9 ). 
Reprints of this article and of individual components of the USPHS/IDSA guidelines
can be obtained from the CDC National AIDS Clearinghouse, P.O. Box 6003, Rockville,
MD 20849-6003. Telephone: (800) 458-5231.
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TABLE 2. Categories reflecting the quality of evidence forming the basis for
recommendations regarding the use of a product or measure for the prevention of
opportunistic infection in HIV-infected persons
Category Definition
I Evidence from at least one properly randomized, controlled trial
II Evidence from at least one well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies (preferably
from more than one center), or from multiple time-series studies or
dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities based on clinical
experience, descriptive studies, or reports of expert committees
NOTE: Modified from Gross et al. (10 ).
TABLE 1. Categories reflecting the strength of each recommendation for or against
the use of a product or measure for the prevention of opportunistic infection in
HIV-infected persons
Category Definition
A Both strong evidence and substantial clinical benefit support a
recommendation for use.
B Moderate evidence—or strong evidence for only limited benefit—supports a
recommendation for use.
C Poor evidence supports a recommendation for or against use.
D Moderate evidence supports a recommendation against use.
E Good evidence supports a recommendation against use.
NOTE: Modified from Gross et al. (10 ).
Categories Reflecting Strength and Quality of Evidence
Supporting Recommendations




(1) Although some authorities recommend that HIV-infected persons at risk for
P. carinii pneumonia (PCP) not share a hospital room with a patient with PCP, data are
insufficient to support this recommendation as standard practice (CIII).
Prevention of Disease
(2) Adults and adolescents with HIV infection (including those who are pregnant)
should receive chemoprophylaxis against PCP if they have a CD4+ lymphocyte count
of <200/gmL (AI), unexplained fever (>100° F) for ≥2 weeks (AII), or a history of oro-
pharyngeal candidiasis (AII).
Trimethoprim-sulfamethoxazole (TMP-SMZ) is the preferred prophylactic agent
(AI). TMP-SMZ may confer cross-protection against toxoplasmosis (AII) and many
bacterial infections (AII). For patients with an adverse reaction that is not life-threaten-
ing, treatment with TMP-SMZ should be continued if clinically feasible; for those who
have discontinued such therapy, its reinstitution should be strongly considered (AII).
Whether it is best to reintroduce the drug at the original dose or at a lower and gradu-
ally increasing dose or to try a desensitization regimen is unknown.
If TMP-SMZ cannot be tolerated, alternative prophylactic regimens include dap-
sone (AI), dapsone plus pyrimethamine plus leucovorin (AI), and aerosolized
pentamidine administered by the Respirgard II nebulizer (Marquest, Englewood, CO)
(AI). Regimens including dapsone plus pyrimethamine are also protective against
toxoplasmosis (AI) but not against most bacterial infections. Because data on their
efficacy for PCP prophylaxis are insufficient, the following regimens generally cannot
be recommended for this purpose: aerosolized pentamidine administered by other
nebulization devices currently available in the United States, intermittently adminis-
tered parenteral pentamidine, oral pyrimethamine/sulfadoxine, oral clindamycin plus
primaquine, oral atovaquone, and intravenous trimetrexate. However, the use of these
agents may be considered in unusual situations in which the recommended agents
cannot be administered (CIII).
Prevention of Recurrence
(3) Adults and adolescents with a history of PCP should receive chemoprophylaxis
with the regimens indicated above to prevent recurrence (AI).
*These recommendations address 17 opportunistic infections or groups of opportunistic infec-
tions and cover prevention of exposure, prevention of the first episode of disease, and
prevention of recurrence (including relapse and reinfection). The recommendations are not
presented in order of priority; the priorities in preventing opportunistic infections in HIV-
infected persons are presented in ‘‘USPHS/IDSA Guidelines for the Prevention of Opportunistic
Infections in Persons Infected with Human Immunodeficiency Virus: An Overview’’ (7 ).
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Notes
Pediatric Notes
(4) Children born to HIV-infected mothers should receive prophylaxis with TMP-
SMZ beginning at 4–6 weeks of age (11 ) (AII). Prophylaxis should be discontinued for
children who are subsequently found not to be infected with HIV. HIV-infected children
and children whose infection status remains unknown should continue to receive
prophylaxis for the first year of life. The need for subsequent prophylaxis should be
determined on the basis of age-specific CD4+ lymphocyte count thresholds (11,12 )
(AII).
(5) Children with a history of PCP should receive chemoprophylaxis as indicated
above to prevent recurrence (AI).
Note Regarding Pregnancy
(6) Chemoprophylaxis for PCP should be administered to pregnant women as to
other adults and adolescents (AIII), although some providers, because of a general
concern about administering drugs during the first trimester of pregnancy, may
choose not to initiate such therapy until after the first trimester. Because of the in-
crease in blood plasma volume and the reduced concentrations of drugs during




(1) HIV-infected persons should be tested for IgG antibody to Toxoplasma soon af-
ter the diagnosis of HIV infection to detect latent infection with Toxoplasma gondii
(BIII).
(2) All HIV-infected persons, but particularly those who lack IgG antibody to
Toxoplasma, should be counseled about the various sources of toxoplasmic infection.
They should be advised not to eat raw or undercooked meat, particularly undercooked
pork, lamb, or venison (BIII). Specifically, meat should be cooked to an internal tem-
perature of 150° F; meat cooked until no longer pink inside generally has an internal
temperature of 165° F and therefore satisfies this requirement. HIV-infected persons
should wash their hands after contact with raw meat and after gardening or other
contact with soil; in addition, they should wash fruits and vegetables well before eat-
ing them raw (BIII). If the patient owns a cat, the litter box should be changed daily,
preferably by an HIV-negative, nonpregnant person; alternatively, the patient should
wash the hands thoroughly after changing the litter box (BIII). Patients should be en-
couraged to keep their cats inside and not to adopt or handle stray cats (BIII). Cats
should be fed only canned or dried commercial food or well-cooked table food, not
raw or undercooked meats (BIII). Patients need not be advised to part with their cats
or to have their cats tested for toxoplasmosis (EII).
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Prevention of Disease
(3) Toxoplasma-seropositive patients with a CD4+ lymphocyte count of <100/gmL
should receive prophylaxis against toxoplasmic encephalitis (TE) (AII). The doses of
TMP-SMZ recommended for PCP prophylaxis appear to be effective against TE as well
(AII). If patients cannot tolerate TMP-SMZ, the regimens including dapsone plus
pyrimethamine that are recommended for PCP prophylaxis provide protection against
TE (AI). Prophylactic monotherapy with dapsone, pyrimethamine, azithromycin,
clarithromycin, or atovaquone cannot be recommended on the basis of current data
(DII). Aerosolized pentamidine does not afford protection against TE (EI).
(4) Toxoplasma-seronegative persons who are not taking a PCP prophylactic regi-
men known to be active against TE should be retested for IgG antibody to Toxoplasma
when their CD4+ lymphocyte count falls below 100/gmL to determine whether they
have seroconverted and are therefore at risk for TE (CIII). Patients who have serocon-
verted should receive prophylaxis for TE as described above (AII).
Prevention of Recurrence
(5) Patients who have had TE should receive lifelong suppressive therapy with
drugs active against Toxoplasma to prevent relapse (AI). The combination
of pyrimethamine plus sulfadiazine and leucovorin is highly effective for this pur-
pose (AII). A commonly used regimen for patients who cannot tolerate sulfa
drugs is pyrimethamine plus clindamycin (AII); however, only the combination of




(6) Current data are insufficient for the formulation of specific guidelines for chil-
dren. The provider should consider the recommendations for adults; children
>12 months of age who are seropositive for IgG antibody to Toxoplasma, have a CD4+
lymphocyte count of <100/µL, and are not already taking medication effective against
Toxoplasma may be considered as candidates for chemoprophylaxis (CIII). Some
providers would consider opting for chemoprophylaxis for very young children with
higher CD4+ lymphocyte counts consistent with severe immunosuppression (12 ) and
with evidence of toxoplasmic infection.
Notes Regarding Pregnancy
(7) Because of the low incidence of TE during pregnancy and the possible risk
associated with pyrimethamine treatment, chemoprophylaxis with pyrimethamine-
containing regimens can reasonably be deferred until after pregnancy for women who
are seropositive for IgG antibody to Toxoplasma (CIII). TMP-SMZ can be administered
as described for prophylaxis of PCP. For prophylaxis of recurrent TE, pyrimethamine
should be used with caution (CIII).
(8) In rare cases, HIV-infected pregnant women with serological evidence of remote
toxoplasmic infection have transmitted Toxoplasma to the fetus in utero. Pregnant
HIV-infected women who have evidence of primary toxoplasmic infection or active
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toxoplasmosis (including TE) should be evaluated during pregnancy in consultation
with appropriate specialists (CIII). Infants born to women with serological evidence of




(1) HIV-infected persons should be educated and counseled about the many ways
that Cryptosporidium can be transmitted. Modes of transmission include contact with
infected adults and diaper-age children, contact with infected animals, consumption
of contaminated drinking water, and contact with contaminated water during recrea-
tional activities (BIII).
(2) HIV-infected persons should avoid contact with human and animal feces. They
should be advised to wash their hands after contact with human feces (e.g., during
diaper changing), after handling of pets, and after gardening or other contact with soil.
HIV-infected persons should avoid sexual practices such as oral-anal intercourse that
may result in oral exposure to feces (BIII).
(3) HIV-infected persons should be advised that newborn and very young pets may
pose a small risk of cryptosporidial infection, but they should not be advised to de-
stroy or give away healthy pets. Persons contemplating the acquisition of a new pet
should avoid bringing any animal with diarrhea into their households, should avoid
purchasing a dog or cat <6 months of age, and should not adopt stray pets. HIV-
infected persons who wish to assume the small risk of acquiring a puppy or kitten
<6 months of age should request that their veterinarian examine the animal’s stool for
Cryptosporidium  before they have contact with the animal (BIII).
(4) HIV-infected persons should avoid exposure to calves and lambs and to prem-
ises where these animals are raised (BII).
(5) HIV-infected persons should not drink water directly from lakes or rivers. Be-
cause water can be accidentally ingested, patients should be advised that swimming
in lakes, rivers, or public swimming pools may put them at increased risk for infection
(BII).
(6) Several outbreaks of cryptosporidiosis have been linked to municipal water sup-
plies. During outbreaks or in other situations in which a community “boil-water”
advisory is issued, boiling of water for 1 minute will eliminate the risk of crypto-
sporidiosis (AI). Use of submicron personal-use water filters* (i.e., home/office types)
and/or bottled water
†
 (2 ) may reduce the risk (CIII). The magnitude of the risk of ac-
quiring cryptosporidiosis from drinking water in a nonoutbreak setting is uncertain,
* Only filters capable of removing particles 1 µm in diameter and larger should be considered. Filters that
provide the greatest assurance of oocyst removal include those that operate by reverse osmosis, those
labeled as “absolute” 1-µm filters, and those labeled as meeting NSF (National Sanitation Foundation)
standard no. 53 for “cyst removal.” The “nominal” 1-µm filter rating is not standardized, and many filters
in this category may not be capable of removing ≥99% of oocysts.
†
Sources of bottled water (wells, springs, municipal tap-water supplies, rivers, lakes) and methods for its
disinfection vary; therefore, all brands should not be presumed to be free of cryptosporidial oocysts.  Water
from wells and springs is much less likely to be contaminated by oocysts than water from rivers or lakes.
Treatment of bottled water by distillation or reverse osmosis ensures oocyst removal. Water passed through
an “absolute” 1-µm filter or a filter labeled as meeting NSF standard no. 53 for “cyst removal” before
bottling will provide nearly the same level of protection. Use of “nominal” 1-µm filters by bottlers as the
only barrier to cryptosporidia may not result in the removal of ≥99% of oocysts.
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and current data are inadequate to recommend that all HIV-infected persons boil or
avoid drinking tap water in nonoutbreak settings. However, HIV-infected persons who
wish to take independent action to reduce the risk of waterborne cryptosporidiosis
may choose to take precautions similar to those recommended during outbreaks.
Such decisions should be made in conjunction with health care providers. Persons
who opt for a personal-use filter or bottled water should be aware of the complexities
involved in selecting appropriate products, the lack of enforceable standards for the
destruction or removal of oocysts, the cost of the products, and the logistic difficulty
of using these products consistently.
Prevention of Disease
(7) No effective chemoprophylactic agents are available for cryptosporidiosis.
Prevention of Recurrence




(9) At present, no data indicate that formula-preparation practices for infants
should be altered in an effort to prevent cryptosporidiosis (CIII).
MICROSPORIDIOSIS
Prevention of Exposure
(1) Other than general attention to hand washing and other personal hygiene meas-
ures, no precautions to reduce exposure can be recommended at this time.
Prevention of Disease
(2) No chemoprophylactic regimens are known to be effective in preventing
microsporidiosis.
Prevention of Recurrence




(1) HIV-infected persons should be advised that certain activities and occupations
may increase the likelihood of exposure to tuberculosis (BIII). These include volunteer
work or employment in health care facilities, correctional institutions, and shelters
for the homeless as well as in other settings identified as high risk by local health
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authorities. Decisions about whether to continue with activities in these settings
should be made in conjunction with the health care provider and should take into
account such factors as the patient’s specific duties in the workplace, the prevalence
of tuberculosis in the community, and the degree to which precautions are taken to
prevent the transmission of tuberculosis in the workplace (BIII). Whether or not the
patient continues with such activities may affect the frequency with which screening
for tuberculosis needs to be conducted.
Prevention of Disease
(2) When HIV infection is first recognized, the patient should be screened by the
Mantoux method with intermediate-strength (5-TU) PPD (AI). Routine evaluation for
anergy is controversial; some experts recommend anergy testing for persons in set-
tings where there is an increased risk of infection with Mycobacterium tuberculosis
(i.e., in areas where the prevalence of such infection is >10%) (CIII).
(3) All HIV-infected persons with a positive result in the tuberculin skin test (TST;
≥5 mm of induration) should undergo chest radiography and clinical evaluation for the
exclusion of active tuberculosis. HIV-infected individuals who have symptoms sug-
gestive of tuberculosis should undergo chest radiography and clinical evaluation
regardless of their TST status (AII).
(4) All HIV-infected persons with a positive TST result who have no evidence of
active tuberculosis and no history of treatment or prophylaxis for tuberculosis should
receive 12 months of preventive chemotherapy with isoniazid (AI). Since HIV-infected
persons are at risk for peripheral neuropathy, those receiving isoniazid should also
receive pyridoxine (BIII). The decision to use alternative antimycobacterial agents for
chemoprophylaxis should be based on the relative risk of exposure to resistant organ-
isms and may require consultation with public health authorities (AII). The need for
direct observation as a means of documenting compliance with chemoprophylaxis
should be considered on an individual basis (BIII).
(5) HIV-infected individuals who are close contacts of persons with infectious tuber-
culosis (i.e., acid-fast bacillary smear-positive pulmonary disease) should receive
preventive therapy—regardless of TST results or prior courses of chemoprophy-
laxis—after active tuberculosis has been excluded (AII). Such persons should be
tested with 5-TU PPD. If the TST result is initially negative, the individual should be
evaluated again 3 months after the discontinuation of contact with the infectious
source, and the information obtained should be considered in the course of decisions
about whether chemoprophylaxis should continue (BIII).
(6) TST-negative, HIV-infected persons from risk groups or geographic areas with a
high prevalence of M. tuberculosis infection (>10%) may be at increased risk of tuber-
culosis. Some experts recommend preventive therapy for anergic individuals or
perhaps for all persons in this category (CIII). However, the efficacy of preventive ther-
apy in this group has not been demonstrated, and decisions concerning the use of
chemoprophylaxis in these situations must be individualized.
(7) Although the reliability of the TST may diminish as the CD4+ lymphocyte count
declines, testing should be repeated at least annually for HIV-infected persons who are
TST-negative on initial evaluation (BIII). In addition to documenting tuberculous infec-
tion, TST conversion in an HIV-infected person should alert health care providers to
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the possibility of an infectious case in the environment and lead to notification of pub-
lic health officials for investigation to identify a possible source case.
(8) The administration of BCG vaccine to HIV-infected persons is contraindicated
because of its potential to cause disseminated disease (EII).
Prevention of Recurrence
(9) Chronic suppressive therapy for a patient who has successfully completed a
recommended regimen of treatment for tuberculosis is not necessary (EII).
Notes
Pediatric Note
(10) All infants born to HIV-infected mothers should have a TST (5-TU PPD) at
9–12 months of age (CIII). All children living in households with M. tuberculosis-in-
fected (TST-positive) persons should be evaluated for tuberculosis (13 ) (CIII); those
exposed to a person with active tuberculosis should receive preventive therapy after
active tuberculosis has been excluded (AII).
Note Regarding Pregnancy
(11) HIV-infected pregnant women who have a positive TST result without evidence
of active tuberculosis should receive standard chemoprophylaxis (AII). When possi-
ble, chest radiography should be undertaken and chemoprophylaxis should be
initiated after the first trimester in order to avoid the critical period of major organo-
genesis. Preventive therapy with isoniazid should be accompanied by treatment with
pyridoxine so that peripheral neuropathy does not develop. Alternative regimens
(e.g., rifampin, rifabutin) should be used with caution during pregnancy.
DISSEMINATED INFECTION WITH MYCOBACTERIUM AVIUM
COMPLEX
Prevention of Exposure
(1) Organisms of the M. avium complex (MAC) are common in environmental
sources such as food and water. Current information does not support specific recom-
mendations regarding avoidance of exposure.
Prevention of Disease
(2) Prophylaxis with rifabutin should be considered for HIV-infected adults and ado-
lescents who have a CD4+ lymphocyte count of <75/µL, although some experts would
wait until the count is <50/µL (BII). Disseminated MAC disease should be ruled out (by
a negative blood culture) before prophylaxis is initiated. Because treatment with ri-
fabutin may result in the development of resistance to rifampin in individuals with
active tuberculosis, the latter condition should be excluded before rifabutin prophy-
laxis is begun. Drug interactions, partial efficacy, and cost are among the other issues
that should be considered in decisions about whether to institute prophylaxis for
MAC disease. Data on the safety and efficacy of clarithromycin, azithromycin, and
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combinations of clarithromycin or azithromycin with rifabutin have not yet been re-
viewed sufficiently to warrant recommendations concerning these regimens.
(3) Although the detection of MAC organisms in the respiratory or gastrointestinal
tract may be predictive of the development of disseminated MAC infection, no data
are available on the efficacy of prophylaxis with rifabutin or other drugs in patients
with MAC organisms at these sites and a negative blood culture. Therefore, routine
screening of respiratory or gastrointestinal specimens for MAC cannot be recom-
mended at this time (DIII).
Prevention of Recurrence
(4) Patients who are treated for disseminated MAC infection should continue to
receive full therapeutic doses for life (BIII). The use of a macrolide, usually clarithromy-
cin, is generally recommended in conjunction with at least one other drug, such as
ethambutol, clofazimine, ciprofloxacin, or rifabutin.
Notes
Pediatric Note
(5) HIV-infected children <12 years of age also develop disseminated MAC infec-
tions. Prophylaxis should be considered similar to that recommended for adults and
adolescents (BI). For children 6–12 years of age, a CD4+ lymphocyte count of <75/µL is
a reasonable threshold for the initiation of chemoprophylaxis. Some adjustment for
age is necessary in the interpretation of CD4+ lymphocyte counts of children <6 years
of age (12 ). No pediatric formulation of rifabutin is currently available, but a dosage of
5 mg/kg has been used in pharmacokinetic studies.
Note Regarding Pregnancy
(6) Information is insufficient for recommendations concerning the use of rifabutin
or clarithromycin during pregnancy.
BACTERIAL RESPIRATORY INFECTIONS
Prevention of Exposure
(1) Because Streptococcus pneumoniae and Haemophilus influenzae are common
in the community, there is no effective way to reduce exposure to these bacteria.
Prevention of Disease
(2) As soon as possible after HIV infection is diagnosed, adults should receive a
single dose of 23-valent polysaccharide pneumococcal vaccine (BIII). This recommen-
dation is especially pertinent in light of the increasing incidence of invasive infections
with drug-resistant strains of S. pneumoniae. Although the administration of protein-
polysaccharide conjugate H. influenzae type b vaccine may be considered, data are
insufficient to recommend the use of this vaccine in HIV-infected adults at this time.
(3) TMP-SMZ, administered daily, may be effective in preventing serious bacterial
respiratory infections (although not those caused by drug-resistant S. pneumoniae);
this fact should be considered in the selection of an agent for PCP prophylaxis (AII).
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However, indiscriminate use of this drug (when not indicated for PCP prophylaxis or
other specific reasons) may promote the development of resistant organisms.
(4) An absolute neutrophil count that is depressed because of HIV disease or
drug therapy may be increased by granulocyte colony-stimulating factor (G-CSF)
or granulocyte-macrophage colony-stimulating factor (GM-CSF). However, data
are insufficient for recommendations concerning the use of G-CSF or GM-CSF to pre-
vent bacterial infections in HIV-infected patients with neutropenia.
Prevention of Recurrence
(5) Some clinicians may choose to offer antibiotic chemoprophylaxis to HIV-
infected patients with recurrent serious bacterial respiratory infections (BIII). TMP-
SMZ, administered for PCP prophylaxis, is appropriate for drug-sensitive organisms.
(6) All invasive pneumococcal isolates from HIV-infected patients should be tested
for susceptibility to β-lactam antibiotics, and local patterns of resistance should be
considered in the choice of regimens for empirical treatment (AII). Invasive infections
due to H. influenzae should be treated with regimens effective against β-lactamase-
producing strains until drug susceptibilities are known (AII).
Notes
Pediatric Notes
(7) Children with HIV infection should receive H. influenzae type b vaccine in ac-
cordance with the guidelines of the Advisory Committee for Immunization Practices
(14 ) and the American Academy of Pediatrics (13 ) (AII). Children >2 years of age
should also receive 23-valent polysaccharide pneumococcal vaccine (BII).
(8) To prevent serious bacterial infections in HIV-infected children with documented
antibody deficiency, clinicians should use intravenous immunoglobulin (IVIG) (AI).
The administration of IVIG should also be considered for HIV-infected children with
recurrent serious bacterial infections (AI), but such treatment may not provide addi-
tional benefit to children receiving daily TMP-SMZ.
Note Regarding Pregnancy




(1) Health care providers should advise HIV-infected persons not to eat raw or un-
dercooked eggs (including foods that may contain raw eggs—e.g., some preparations
of hollandaise sauce, Caesar and other salad dressings, and mayonnaise); raw or un-
dercooked poultry, meat, or seafood; or unpasteurized dairy products. Poultry and
meat should be well cooked and should not be pink in the middle (internal tempera-
ture, >165° F). Produce should be thoroughly washed before being eaten (BIII).
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(2) Health care providers should advise HIV-infected persons to avoid cross-
contamination of foods. For example, uncooked meats should not come into contact
with other foods, and hands, cutting boards, counters, and knives and other utensils
should be washed thoroughly after contact with uncooked foods (BIII).
(3) Health care providers should advise HIV-infected persons that, although the
incidence of listeriosis is low, it is a serious disease that occurs with unusually high
frequency among HIV-infected persons who are severely immunosuppressed. Such
persons may choose to avoid soft cheeses because some studies have shown an as-
sociation between these foods and listeriosis. These studies have also documented an
association between ready-to-eat foods (e.g., hot dogs and cold cuts from delicates-
sen counters) and listeriosis. An immunosuppressed, HIV-infected person who wishes
to reduce the risk of food-borne disease as much as possible may choose to re-heat
such foods until they are steaming hot before eating them (CIII).
Pets
(4) When obtaining a new pet, HIV-infected persons should avoid young animals
(<6 months of age), especially those with diarrhea (BIII).
(5) HIV-infected persons should avoid contact with animals that have diarrhea (BIII).
HIV-infected pet owners should seek veterinary care for animals with diarrheal illness,
and a fecal sample from such animals should be examined for Cryptosporidium, Sal-
monella, and Campylobacter.
(6) HIV-infected persons should wash their hands after handling pets (especially
before eating) and should avoid contact with pets’ feces (BIII).
(7) HIV-infected persons should avoid contact with reptiles (such as snakes, lizards,
and turtles) because of the risk of salmonellosis (BIII).
Travel
(8) The risk of food- and waterborne infections among immunosuppressed, HIV-
infected persons is magnified during travel to developing countries. Those who elect
to travel to such countries should avoid foods and beverages that may be contami-
nated, particularly raw fruits and vegetables, raw or undercooked seafood or meat,
tap water, ice made with tap water, unpasteurized milk and dairy products, and items
sold by street vendors (AII). Foods and beverages that are generally safe include
steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbon-
ated) beverages, hot coffee and tea, beer, wine, and water brought to a rolling boil for
1 minute (AII). Treatment of water with iodine or chlorine may not be as effective as
boiling but can be used when boiling is not practical (BIII).
Prevention of Disease
(9) Prophylactic antimicrobial agents are not generally recommended for travelers
(DIII). The effectiveness of these agents depends upon local antimicrobial-resistance
patterns of gastrointestinal pathogens, which are seldom known. Moreover, these
agents can elicit adverse reactions and can promote the emergence of resistant
organisms. However, for HIV-infected travelers, antimicrobial prophylaxis may be
considered, depending upon the level of immunosuppression and the region and du-
ration of travel (CIII).
14 MMWR July 14, 1995
The use of fluoroquinolones—such as ciprofloxacin (500 mg/d)—can be considered
when prophylaxis is deemed necessary (BIII). As an alternative (e.g., for children,
pregnant women, and persons already taking TMP-SMZ for PCP prophylaxis), TMP-
SMZ may offer some protection against traveler’s diarrhea (BIII). The risk of toxicity
should be considered before treatment with TMP-SMZ is initiated solely because of
travel.
(10) Antimicrobial agents such as fluoroquinolones (e.g., 500 mg of ciprofloxacin
b.i.d. for 3–7 days) should be given to patients before their departure, to be taken
empirically should traveler’s diarrhea develop (BIII). Alternative antibiotics for children
and pregnant women should be discussed (CIII). Travelers should consult a physician
if their diarrhea is severe and does not respond to empirical therapy, if their stools
contain blood, if fever is accompanied by shaking chills, or if dehydration develops.
Antiperistaltic agents such as diphenoxylate and loperamide can be used for the treat-
ment of mild diarrhea. However, the use of these drugs should be discontinued if
symptoms persist beyond 48 hours. Moreover, these agents should not be given to
patients with high fever or with blood in the stool (AII).
(11) Some experts recommend that HIV-infected persons with salmonella gastroen-
teritis receive antimicrobial therapy to prevent extraintestinal spread. However, no
controlled study has demonstrated a beneficial effect of such treatment, and some
studies of immunocompetent persons have suggested that antimicrobial therapy can
lengthen the shedding period. The fluoroquinolones—primarily ciprofloxacin (750 mg
b.i.d. for 14 days)—can be used when antimicrobial therapy is opted for (CIII).
Prevention of Recurrence
(12) HIV-infected persons with salmonella septicemia require long-term therapy for
the prevention of recurrence. The fluoroquinolones, primarily ciprofloxacin, are usu-
ally the drugs of choice for susceptible organisms (BII).
(13) Household contacts of HIV-infected persons with salmonellosis or shigellosis
should be evaluated for asymptomatic carriage of Salmonella or Shigella so that strict
hygienic measures and/or antimicrobial therapy can be instituted and recurrent trans-
mission to the HIV-infected person can be prevented (CIII).
Notes
Pediatric Notes
(14) Like HIV-infected adults, HIV-infected children should wash their hands after
handling pets (especially before eating) and should avoid contact with pets’ feces.
Hand washing should be supervised (BIII).
(15) HIV-exposed infants <3 months of age and all HIV-infected children with severe
immunosuppression should receive treatment for salmonella gastroenteritis to
prevent extraintestinal spread. Possible choices of antibiotics include TMP-SMZ,
ampicillin, cefotaxime, ceftriaxone, or chloramphenicol; ciprofloxacin may be consid-
ered for the treatment of children >6 years of age (CIII).
(16) HIV-infected children with salmonella septicemia require long-term therapy for
the prevention of recurrence. TMP-SMZ is the drug of choice; ampicillin or chloram-
phenicol can be used if the organism is susceptible. Ciprofloxacin may be considered
for the treatment of children >6 years of age (CIII).
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(17) Antiperistaltic drugs are not recommended for children (DIII).
Notes Regarding Pregnancy
(18) Since both pregnancy and HIV infection confer a risk for listeriosis, pregnant
HIV-infected women should pay particular attention to recommendations concerned
with this disease (BII).
(19) Fluoroquinolones should not be used during pregnancy. TMP-SMZ may offer
some protection against traveler’s diarrhea.
INFECTION WITH BARTONELLA (FORMERLY ROCHALIMAEA)
Prevention of Exposure
(1) HIV-infected persons, particularly those who are severely immunosuppressed,
are at unusually high risk of developing relatively severe disease due to Bartonella
species. These individuals should consider the potential risks of cat ownership (CIII).
Those who elect to acquire a cat should adopt or purchase an older animal (>1 year of
age) that is in good health (BII).
(2) Although declawing is not generally advised, HIV-infected persons should
avoid rough play with cats and situations in which scratches are likely (BII). Any cat-
associated wound should be washed promptly (CIII). HIV-infected persons should not
allow cats to lick open cuts or wounds (BIII).
(3) Care of cats should include flea control (CIII).
(4) There is no evidence of benefit to cat or owner from routine culture or serologi-
cal testing of the pet for Bartonella infection (DII).
Prevention of Disease
(5) No data currently support chemoprophylaxis for Bartonella-associated disease
(CIII).
Prevention of Recurrence
(6) Relapse or reinfection with Bartonella has sometimes followed a course of
primary treatment. Although no firm recommendation can be made regarding pro-
phylaxis in this situation, long-term suppression of infection with erythromycin or
doxycycline should be considered (CIII).
Note
Pediatric Note
(7) The risks of cat ownership for HIV-infected children who are severely immuno-
compromised should be discussed with parents/caretakers (CIII).
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CANDIDIASIS
Prevention of Exposure
(1) Candida organisms are common on mucosal surfaces and skin. No measures
are available to reduce exposure to these fungi.
Prevention of Disease
(2) Although data from a prospective controlled trial indicate that fluconazole can
reduce the risk of mucosal (oropharyngeal, esophageal, and vaginal) candidiasis in
patients with advanced HIV disease, routine primary prophylaxis is not recommended
because of the effectiveness of therapy for acute disease, the low mortality associated
with mucosal candidiasis, the potential for resistant Candida organisms to develop,
the possibility of drug interactions, and the cost of prophylaxis (DII).
Prevention of Recurrence
(3) Many experts do not recommend chronic prophylaxis of recurrent oro-
pharyngeal or vulvovaginal candidiasis for the same reasons that they do not
recommend primary prophylaxis. However, if recurrences are frequent or severe, in-
termittent or chronic administration of topical nystatin, topical clotrimazole, or an oral
azole (ketoconazole, fluconazole, or itraconazole) may be considered (BI). Other fac-
tors that influence choices about such therapy include the impact of the recurrences
on the patient’s well-being and quality of life, the need for prophylaxis for other fungal
infections, cost, toxicities, and drug interactions.
(4) Adults or adolescents with a history of documented esophageal candidiasis,
particularly multiple episodes, should be considered candidates for chronic suppres-
sive therapy with fluconazole (BI).
Notes
Pediatric Notes
(5) Primary prophylaxis of candidiasis in HIV-infected infants is not indicated (DII).
(6) Suppressive therapy with systemic azoles should be considered for infants with




(1) Although HIV-infected persons cannot avoid exposure to Cryptococcus neofor-
mans  completely, avoiding sites that are likely to be heavily contaminated with
C. neoformans  (e.g., areas heavily contaminated with pigeon droppings) may reduce
the risk of infection.
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Prevention of Disease
(2) Because of the low probability that the results will affect clinical decisions,
routine testing of asymptomatic persons for serum cryptococcal antigen is not recom-
mended (DIII).
(3) Data from a prospective controlled trial indicate that fluconazole can reduce the
frequency of cryptococcal disease among patients with advanced HIV disease; thus,
physicians may wish to consider chemoprophylaxis for adult and adolescent patients
with a CD4+ lymphocyte count of <50/µL (BI). However, such prophylaxis should not
be offered routinely because of the relative infrequency of cryptococcal disease, the
possibility of drug interactions, the potential for development of resistance, and the
cost of prophylaxis (DII). The need for prophylaxis or suppressive therapy for other
fungal infections (e.g., candidiasis) should be considered in the course of decisions
about prophylaxis for cryptococcosis.
Prevention of Recurrence
(4) Patients who complete initial therapy for cryptococcosis should receive lifelong
suppressive treatment with fluconazole (AI).
Notes
Pediatric Note
(5) There are no data on which to base specific recommendations for children, but
lifelong suppressive therapy with fluconazole after an episode of cryptococcosis is
appropriate (CIII).
Note Regarding Pregnancy
(6) Although treatment with fluconazole is indicated to prevent the recurrence of
cryptococcosis, this drug should be used with caution in pregnant women (CIII). At
high doses, fluconazole has been associated with both fetal death and increased rates
of fetal abnormalities in rats.
HISTOPLASMOSIS
Prevention of Exposure
(1) Although HIV-infected persons living in or visiting histoplasmosis-endemic
areas cannot completely avoid exposure to Histoplasma capsulatum, they should
avoid activities known to be associated with increased risk (e.g., cleaning chicken
coops, disturbing soil beneath bird-roosting sites, and exploring caves) (CIII).
Prevention of Disease
(2) Routine skin testing with histoplasmin in histoplasmosis-endemic areas is not
predictive of disease and should not be performed (EII).
(3) No recommendation can be made regarding chemoprophylaxis for HIV-infected
persons in histoplasmosis-endemic areas or for histoplasmin-positive persons in
nonendemic areas.
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Prevention of Recurrence
(4) Patients who complete initial therapy should receive lifelong suppressive treat-
ment with itraconazole (AII).
Note
Pediatric Note
(5) Because primary histoplasmosis can lead to disseminated infection in children,




(1) Although HIV-infected persons living in or visiting areas in which coccidioi-
domycosis is endemic cannot completely avoid exposure to Coccidioides immitis,
they should, when possible, avoid activities associated with increased risk (e.g., those
involving extensive exposure to disturbed soil as occurs at building excavation sites,
on farms, or during dust storms) (CIII).
Prevention of Disease
(2) Routine skin testing with coccidioidin (spherulin) in coccidioidomycosis-
endemic areas is not predictive of disease and should not be performed (EII).
(3) No recommendation can be made regarding routine chemoprophylaxis for
HIV-infected individuals who live in coccidioidomycosis-endemic areas or for skin test-
positive persons in nonendemic areas.
Prevention of Recurrence
(4) Patients who complete initial therapy for coccidioidomycosis should receive
lifelong systemic suppressive treatment (AII). Fluconazole is the preferred agent; alter-
native drugs include itraconazole, ketoconazole, and amphotericin B.
Note
Pediatric Note
(5) Although no specific data are available on coccidioidomycosis in HIV-infected
children, it is reasonable to administer lifelong suppressive therapy after an acute epi-
sode of the disease (CIII).
CYTOMEGALOVIRUS DISEASE
Prevention of Exposure
(1) HIV-infected persons who belong to risk groups with relatively low rates of sero-
positivity for cytomegalovirus (CMV) and who anticipate possible exposure to CMV
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(e.g., through blood transfusion or employment in a child-care facility) should be
tested for antibody to CMV (BIII). These groups include patients who have not had
male homosexual contact and those who are not injection drug users.
(2) HIV-infected adolescents and adults should be advised that CMV is shed in se-
men, cervical secretions, and saliva and that latex condoms must always be used
during sexual contact to reduce the risk of exposure to this virus and to other sexually
transmitted pathogens (AII).
(3) HIV-infected adults and adolescents who are child-care providers or parents of
children in child-care facilities should be informed that they—like all children at these
facilities—are at increased risk of acquiring CMV infection (BI). Parents and other care-
takers of HIV-infected children should be advised of the increased risk to children at
these centers (BIII). The risk of acquiring CMV infection can be diminished by good
hygienic practices, such as hand washing (AII).
(4) HIV-exposed infants and HIV-infected children, adolescents, and adults who
are seronegative for CMV and require blood transfusion should receive only CMV
antibody-negative or leukocyte-reduced cellular blood products in nonemergency
situations (15 ) (BIII).
Prevention of Disease
(5) Data on the efficacy and safety of oral ganciclovir have not yet been adequately
reviewed; thus no recommendation concerning this drug can be made at this time.
Acyclovir is not effective in preventing CMV disease (EII). Since no chemoprophylactic
agent is currently available, the most important method for preventing severe CMV
disease is recognition of the early manifestations of the disease. Early recognition of
CMV retinitis is most likely when the patient has been educated on this topic and un-
dergoes regular funduscopic examinations performed by a health care provider (CIII).
Patients should be made aware of the significance of increased “floaters” in the eye
and should be advised to assess their visual acuity regularly by simple techniques
such as reading newsprint (BIII).
Prevention of Recurrence
(6) CMV disease is not cured with courses of the currently available antiviral agents
ganciclovir and foscarnet. Chronic suppressive or maintenance therapy is indicated.
The presently approved regimens include parenteral or oral ganciclovir or parenteral
foscarnet (AI). In spite of maintenance therapy, recurrences develop routinely and re-
quire reinstitution of high-dose induction therapy.
Note
Pediatric Note
(7) The recommendations for the prevention of CMV disease and of its recurrence
apply to children as well as to adolescents and adults. However, oral ganciclovir has
not been studied in children.
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HERPES SIMPLEX VIRUS DISEASE
Prevention of Exposure
(1) HIV-infected persons should use latex condoms during every act of sexual inter-
course to reduce the risk of exposure to herpes simplex virus (HSV) and to other
sexually transmitted pathogens (AII). They should specifically avoid sexual contact
when herpetic lesions (genital or orolabial) are evident (AII).
Prevention of Disease
(2) Prophylaxis of initial episodes of HSV disease is not recommended (DIII)*.
Prevention of Recurrence
(3) Because acute episodes of HSV infection can be treated successfully, chronic
therapy with acyclovir is not required after lesions resolve. However, persons with
frequent or severe recurrences can be given daily suppressive therapy with oral acy-
clovir (AI). Intravenous foscarnet can be used for the treatment of infection due to




(4) The recommendations for the prevention of initial disease and recurrence apply
to children as well as to adolescents and adults.
Note Regarding Pregnancy
(5) The effectiveness of suppressive treatment with acyclovir in reducing the risk of
perinatal HSV transmission has not been studied. Therefore, no relevant recommen-
dation can be made.
VARICELLA-ZOSTER VIRUS INFECTION
Prevention of Exposure
(1) HIV-infected children and adults who are susceptible to varicella-zoster virus
(VZV)—i.e., those who have no history of chickenpox or are seronegative for VZV—
should avoid exposure to persons with chickenpox or shingles (AII).
Prevention of Disease
(2) For the prophylaxis of chickenpox, HIV-infected children and adults who are sus-
ceptible to VZV should be given zoster immune globulin within 96 hours after close
contact with a patient with chickenpox or shingles (AI). Data are lacking on the effec-
tiveness of acyclovir for preventing chickenpox in HIV-infected children or adults.
*Controversy exists over the possible association of acyclovir therapy with prolonged survival
of HIV-infected persons.  Current data suggest that chronic acyclovir therapy may be consid-
ered but should not be standard practice (CIII).
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(3) No preventive measures are currently available for shingles.
Prevention of Recurrence




(5) Zoster immune globulin is not contraindicated during pregnancy and should be
given to VZV-susceptible pregnant women after exposure to VZV (AI).
HUMAN PAPILLOMAVIRUS INFECTION
Prevention of Exposure
(1) HIV-infected persons should use latex condoms during every act of sexual inter-
course to reduce the risk of exposure to human papillomavirus (HPV) as well as to
other sexually transmitted pathogens (AII).
Prevention of Disease
HPV-Associated Genital Epithelial Cancers in HIV-Infected Women
(2) HIV-infected women should have annual cervical Pap smears as part of their
initial and routine gynecologic care. In accordance with the recommendation of the
Agency for Health Care Policy and Research (9 ), a Pap smear should be obtained
twice in the first year after diagnosis of HIV infection and, if the results are normal,
annually thereafter (AII).
(3) If an HIV-infected woman has a history of abnormal Pap smears, the caregiver
may choose to monitor this individual with Pap smears every 6 months (BIII).
(4) If the initial or follow-up Pap smear indicates inflammation with reactive
squamous cellular changes, further management should be guided by diagnosis of
the cause of the inflammation, and another Pap smear should be collected within
3 months (BIII). HIV-infected women with Pap smears showing only atypical cells of
undetermined significance can be monitored with annual Pap smears (BIII).
(5) Controversy exists concerning the management of HIV-infected women with
low-grade squamous intraepithelial lesions (SIL) evident on the cervical Pap smear;
the natural history of this finding in this population has not yet been well defined.
Some experts would collect another Pap smear within 3 months. If subsequent Pap
smears again showed low-grade SIL, some of these authorities would refer the patient
for colposcopic evaluation and biopsy (if indicated); while others would monitor com-
pliant patients with repeat Pap smears at frequent intervals (e.g., every 3–6 months)
(BIII). Other experts would refer all HIV-infected patients with low-grade SIL for
colposcopy (BIII).
(6) If a Pap smear indicates high-grade SIL or squamous cell carcinoma, the woman
should be referred for colposcopic examination and, if indicated, colposcopically di-
rected biopsy (AI).
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HPV-Associated Anal Intraepithelial Neoplasia and Anal Cancer in
HIV-Infected Men Who Have Sex with Men
(7) Although the risks for anal intraepithelial neoplasia (AIN) and anal cancer are
increased among HIV-infected men who have sex with men, the role of anal cytologi-
cal screening and treatment of AIN in preventing anal cancer in these men is not well
defined. Therefore, no recommendations can be made for periodic anal cytological
screening for the detection and treatment of AIN.
Prevention of Recurrence
(8) The risks for recurrence of SIL and cervical cancer after conventional therapy are
increased among HIV-infected women. The prevention of illness associated with re-
currence depends on careful follow-up of patients after treatment. Patients should be
monitored with frequent cytological screening and, when indicated, with colposcopic
examination for recurrent lesions (AI).
Note
Pediatric Note
(9) Newborns have been known to acquire laryngeal HPV from their mothers. No
recommendations can currently be made to prevent such acquisition.
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TABLE 3A. Prophylaxis for first episode of opportunistic disease in HIV-infected adults
and adolescents
Preventive regimens
Pathogen Indication First choice Alternatives
I. Strongly recommended as
standard of care
Pneumocystis carinii* CD4+ count of <200/µL or
unexplained fever for ≥2 w
or oropharyngeal
candidiasis
TMP-SMZ, 1 DS po q.d. (AI) TMP-SMZ, 1 SS po q.d. (AI) or
1 DS po t.i.w. (AII); dapsone,
50 mg po b.i.d. or 100 mg
po q.d., (AI); dapsone,
50 mg po q.d., plus
pyrimethamine, 50 mg po
q.w., plus leucovorin, 25 mg
po q.w. (AI); dapsone,
200 mg po q.w., plus
pyrimethamine, 75 mg po
q.w., plus leucovorin, 25 mg
po q.w. (AI); aerosolized
pentamidine, 300 mg q.m.




 Isoniazid-sensitive TST reaction of ≥5 mm or
prior positive TST result
without treatment or
contact with case of active
tuberculosis
Isoniazid, 300 mg po, plus
pyridoxine, 50 mg po q.d. x
12 mo (AI); or isoniazid,
900 mg po, plus pyridoxine,
50 mg po b.i.w. x 12 mo
(BIII)
Rifampin, 600 mg po q.d. x
12 mo (BII)
 Isoniazid-resistant Same as above; high
probability of exposure to
isoniazid-resistant
tuberculosis
Rifampin, 600 mg po q.d. x
12 mo (BII)




Same as above; high
probability of exposure to
multidrug-resistant
tuberculosis




Toxoplasma gondii§ IgG antibody to Toxoplasma
and CD4+ count of <100/µL
TMP-SMZ, 1 DS po q.d. (AII) TMP-SMZ, 1 SS po q.d. or 1
DS po t.i.w. (AII); dapsone,
50 mg po q.d., plus
pyrimethamine, 50 mg po
q.w., plus leucovorin, 25 mg
po q.w. (AI)
II. Recommended for
consideration in all patients
Streptococcus pneumoniae¶ All patients Pneumococcal vaccine,




CD4+ count of <75/µL Rifabutin, 300 mg po q.d. (BII) Clarithromycin, 500 mg po
b.i.d. (CIII); azithromycin,
500 mg po t.i.w. (CIII)







5–10 µg/kg sc q.d. x 2–4 w;
or granulocyte-macrophage
colony-stimulating factor,
250 µg/m2, i v over 2 h q.d. x
2–4 w (CIII)
None
Candida species CD4+ count of <50/µL Fluconazole, 100–200 mg po
q.d. (CI)
Ketoconazole, 200 mg po q.d.
(CIII)
Drug Regimens for Adults and Adolescents
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TABLE 3A. Prophylaxis for first episode of opportunistic disease in HIV-infected adults
and adolescents
Preventive regimens
Pathogen Indication First choice Alternatives
Cryptococcus neoformans†† CD4+ count of <50/µL Fluconazole, 100–200 mg po
q.d. (BI)
Itraconazole, 200 mg po q.d.
(CIII)
Histoplasma capsulatum†† CD4+ count of <50/µL,
endemic geographic area
Itraconazole, 200 mg po q.d.
(CIII)
Fluconazole, 200 mg po q.d.
(CIII)
Coccidioides immitis†† CD4+ count of <50/µL,
endemic geographic region
Fluconazole, 200 mg po q.d.
(CIII)
Itraconazole, 200 mg po q.d.
(CIII)
CMV§§ CD4+ count of <50/µL and
CMV antibody positivity
Oral ganciclovir, 1 g po t.i.d.
(CIII; only preliminary data
available)
None
Unknown (herpesviruses?)¶¶ CD4+ count of <200/µL Acyclovir, 800 mg po q.i.d.
(CIII)




Hepatitis B virus¶ All susceptible
(anti-HBc-negative) patients
Energix-B, 20 µg im x 3 (BII);
or Recombivax HB, 10 µg
im x 3 (BII)
None
Influenza virus¶ All patients (annually, before
influenza season)
Whole or split virus, 0.5 mL
im/y (BIII)
Rimantadine, 100 mg po b.i.d.
(CIII); or amantadine,
100 mg po b.i.d. (CIII)†††
 — Continued
     NOTE. Not all of the recommended regimens reflect current Food and Drug Administration-approved
labeling. Anti-HBc = antibody to hepatitis B core antigen; b.i.w. = twice weekly; CMV = cytomegalovirus;
DS = double-strength tablet; q.m. = monthly; q.w. = weekly; ss = single-strength tablet; t.i.w. = three
times weekly; TMP-SMZ = trimethoprim-sulfamethoxazole; and TST = tuberculin skin test. The
Respirgard II nebulizer is manufactured by Marquest, Englewood, CO; Energix-B by SmithKline
Beecham, Rixensart, Belgium; and Recombivax HB by Merck & Co., West Point, PA. Letters and Roman
numerals in parentheses after regimens indicate the strength of the recommendation and the quality
of the evidence supporting it (see text).
  * Patients receiving dapsone should be tested for glucose-6-phosphate dehydrogenase deficiency. A
dosage of 50 mg q.d. is probably less effective than a dosage of 100 mg q.d. The efficacy of parenteral
pentamidine (e.g., 4 mg/kg/q.m.) is uncertain. Inadequate data are available on the efficacy and safety
of atovaquone or clindamycin/primaquine. Sulfadoxine/pyrimethamine (Fansidar, Roche Laboratories,
Nutley, NJ) is rarely used because it can elicit severe hypersensitivity reactions. TMP-SMZ and
dapsone/pyrimethamine (and possibly dapsone alone) appear to be protective against toxoplasmosis.
TMP-SMZ may reduce the frequency of some bacterial infections. Patients receiving therapy for
toxoplasmosis with sulfadiazine/pyrimethamine are protected against P. carinii pneumonia and do not
need TMP-SMZ.
†
Directly observed therapy is required for 900 mg of isonizid b.i.w.; isoniazid regimens should include
pyridoxine to prevent peripheral neuropathy. Exposure to multidrug-resistant tuberculosis may require
prophylaxis with two drugs; consult public health authorities. Possible regimens include pyrazinamide
plus either ethambutol or a fluoroquinolone (16 ).
§
Protection against T. gondii is provided by the preferred antipneumocystis regimens. Pyrimethamine
alone probably provides little, if any, protection. Dapsone alone cannot be recommended on the basis
of currently available data.
¶
Data are inadequate concerning clinical benefit of vaccines against S. pneumoniae, influenza virus, and
hepatitis B virus in HIV-infected persons, although it is logical to assume that those patients who develop
antibody responses will derive some protection. Some authorities are concerned that immunizations
may stimulate the replication of HIV. Prophylaxis with TMP-SMZ may provide some clinical benefit by
reducing the frequency of bacterial infections, but the prevalence of S. pneumoniae resistant to
TMP-SMX is increasing. Hepatitis B vaccine has been recommended for all children and adolescents
and for all adults with risk factors for hepatitis B infection. For additional information regarding
vaccination against hepatitis B and vaccination and antiviral therapy against influenza, (17–19 ).
 ** Data on 500 mg of clarithromycin po b.i.d. have been presented but have not yet been thoroughly
analyzed. Data on the efficacy and safety of azithromycin prophylaxis are not yet available. 
††
There may be a few unusual occupational or other circumstances under which prophylaxis should be
considered; consult a specialist.
§§
Data on oral ganciclovir are still being evaluated; the durability of its effect is unclear. Acyclovir is not
protective against CMV.
¶¶
Data regarding the efficacy of acyclovir for prolonging survival are controversial; if acyclovir is beneficial,
the biologic basis for the effect and the optimal dose and timing of therapy are uncertain.
*** These immunizations or chemoprophylactic regimens are not targeted against pathogens traditionally
classified as opportunistic but should be considered for use in HIV-infected patients. While the use of
those products is logical, their clinical efficacy has not been validated in this population.
†††
During outbreaks of influenza A.
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TABLE 3B. Prophylaxis for recurrence of opportunistic disease (after chemotherapy
for acute disease) in HIV-infected adults and adolescents
Preventive regimens
Pathogen Indication First choice Alternatives
I. Recommended for life as
standard of care
Pneumocystis carinii Prior P. carinii pneumonia TMP-SMZ, 1 DS po q.d. (AI) TMP-SMZ, 1 SS po q.d. (AI) or 1 DS
po t.i.w. (AII); dapsone, 50 mg po
b.i.d. or 100 mg po q.d. (AI);
dapsone, 50 mg po q.d., plus
pyrimethamine, 50 mg po q.w.,
plus leucovorin, 25 mg po q.w. (AI);
dapsone, 200 mg po q.w., plus
pyrimethamine, 75 mg po q.w.,
plus leucovorin, 25 mg po q.w. (AI);
aerosolized pentamidine, 300 mg
q.m. via Respirgard II nebulizer (AI)
Toxoplasma gondii* Prior toxoplasmic
encephalitis
Sulfadiazine, 1.0–1.5 g po
q6h, plus pyrimethamine,
25–75 mg po q.d., plus
leucovorin, 10–25 mg po
q.d.–q.i.d. (AII)
Clindamycin, 300–450 mg po q6–8h,
plus pyrimethamine, 25–75 po q.d.,






Clarithromycin, 500 mg po
b.i.d., plus one or more of
the following:
ethambutol, 15 mg/kg po
q.d.; clofazimine, 100 mg
po q.d.; rifabutin, 300 mg
po q.d.; ciprofloxacin,
500–750 mg po b.i.d. (BIII)
Azithromycin, 500 mg po q.d., plus
one or more of the following:
ethambutol, 15 mg/kg po q.d.;
clofazimine, 100 mg po q.d.;
rifabutin, 300 mg po q.d.;
ciprofloxacin, 500-750 mg po b.i.d.
(BIII)
Cytomegalovirus§ Prior end-organ disease Ganciclovir, 5–6 mg/kg iv
5–7 d/w or 1,000 mg po
t.i.d. (AI); or foscarnet,
90–120 mg/kg iv q.d. (AI)
Sustained-release implants used
investigationally
Cryptococcus neoformans Documented disease Fluconazole, 200 mg po
q.d. (AI)
Itraconazole, 200 mg po q.d. (BIII);
amphotericin B, 0.6–1.0 mg/kg iv
q.w.–t.i.w. (AI)
Histoplasma capsulatum Documented disease Itraconazole, 200 mg po
b.i.d. (AII)
Amphotericin B, 1.0 mg/kg iv q.w.
(AI); fluconazole, 200-400 mg po
q.d. (BIII)
Coccidiodes immitis Documented disease Fluconazole, 200 mg po
q.d. (AII)
Amphotericin B, 1.0 mg/kg iv q.w.
(AI); itraconazole, 200 mg po b.i.d.




Bacteremia Ciprofloxacin 500 mg po
b.i.d. for several months
(BII)
None
II. Recommended only if
subsequent episodes
are frequent or severe
Herpes simplex virus Frequent/severe
recurrences
Acyclovir, 200 mg po t.i.d.








Ketoconazole, 200 mg po q.d. (BII);
itraconazole, 100 mg po q.d. (BII);
clotrimazole troche, 10 mg po 5X/d
(BII); nystatin, 5X105 U po 5X/d (CIII)
     NOTE. Not all of the recommended regimens reflect current Food and Drug Administration-approved
labeling. DS = double-strength tablet; q.m. = monthly; q.w. = weekly; SS = single-strength tablet; t.i.w. =
three times weekly; and TMP-SMZ = trimethoprim-sulfamethoxazole. The Respirgard II nebulizer is manu-
factured by Marquest, Englewood, CO. Letters and Roman numerals in parentheses after regimens indicate
the strength of the recommendation and the quality of the evidence supporting it (see text).
* Only pyrimethamine/sulfadiazine confers protection against P. carinii pneumonia.
†
The long-term efficacy of any regimen is not well established. Many multiple-drug regimens are poorly
tolerated. Drug interactions (e.g., those seen with clarithromycin/rifabutin) can be problematic. Rifabutin has
been associated with uveitis, especially when given at daily doses of >300 mg or along with fluconazole or
clarithromycin.
§
Gangiclovir and foscarnet delay relapses by only modest intervals (often only 4–8 weeks). Ocular implants
with sustained-release gangiclovir appear promising.
¶
Efficacious eradication of Salmonella has been demonstrated only for ciprofloxacin.
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TABLE 4A. Prophylaxis for first episode of opportunistic disease in HIV-infected infants
and children
Preventive regimens
Pathogen Indication First choice Alternatives
I. Strongly recommended as
standard of care




<12 mo old; HIV-infected
children 1–5 y old with CD4+
count of <500/µL or CD4+
percentage of <15%;
HIV-infected children 6–12 y
old with CD4+ count of
<200/µL or CD4+ percentage
of <15%
TMP-SMZ, 150/750 mg/m2/d
in 2 divided doses po t.i.w.
on consecutive days (AII);
acceptable alternative
schedules for same dosage
(AII); single dose po t.i.w. on
consecutive days, 2 divided
doses po q.d., or 2 divided
doses po t.i.w. on alternate
days
Aerosolized pentamidine
(children ≥5 y old), 300 mg
q.m. via Respirgard II
nebulizer (CIII); dapsone
(children ≥1 mo old),
2 mg/kg (not to exceed
100 mg) po q.d. (CIII); iv
pentamidine, 4 mg/kg every
2–4 w (CIII)
Mycobacterium tuberculosis
 Isoniazid-sensitive TST reaction of ≥5 mm or
prior positive TST result
without treatment or
contact with case of active
tuberculosis
Isoniazid, 10–15 mg/kg
(maximum, 300 mg) po or
im q.d. X 12 mo or
20–30 mg/kg (maximum,
900 mg) po b.i.w. X 12 mo
(BIII)
Rifampin, 10–20 mg/kg
(maximum, 600 mg) po or
iv q.d. X 12 mo (BII)
 Isoniazid-resistant Same as above; high




(maximum, 600 mg) po or




Same as above; high
probability of exposure to
multidrug-resistant
tuberculosis




Varicella-zoster virus Significant exposure to
varicella with no history of
varicella
VZIG, 1 vial (1.25 mL)/10 kg
(maximum, 5 vials) im,
given ≤96 h after exposure,
ideally within 48 h (AI)
(Children routinely
receiving IVIG should
receive VZIG if the last dose
of IVIG was given >14 d
before exposure.)
None
Various pathogens HIV exposure/infection Immunizations** None
II. Recommended for
consideration in all patients





considered at higher CD4+
counts in the youngest
infants, but no relevant data
are available.)
TMP-SMZ, 150/750 mg/m2/d
in 2 divided doses po t.i.w.
on consecutive days (CIII);
acceptable alternative
schedules for same dosage
(CIII): single dose po t.i.w.
on consecutive days,
2 divided doses po q.d., or
2 divided doses po t.i.w. on
alternate days
Dapsone (children ≥1 mo old),
2 mg/kg or 15 mg/m2
(maximum, 25 mg) po q.d.,
plus pyrimethamine,
1 mg/kg po q.d., plus




CD4+ count of <75/µL Children 6–12 y old: rifabutin,
300 mg po q.d. (BI); children




7.5 mg/kg in 2 divided
doses po q.d. (CIII);
clarithromycin, 5–12 mg/kg
po q.d. (CIII)




Invasive bacterial infections Hypogammaglobulinemia IVIG, 400 mg/kg q.m. (AI) None
Candida species§ Severe immunosuppression Nystatin (100,000 U/mL),
4–6 mL po q6h; or topical
clotrimazole, 10 mg po 5X/d
(CII)
Ketoconazole, 5–10 mg/kg po
q12–24h (CI); fluconazole,
2–8 mg/kg po q.d. (CI)
Drug Regimens for Children
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TABLE 4A. Prophylaxis for first episode of opportunistic disease in HIV-infected infants
and children
Preventive regimens
Pathogen Indication First choice Alternatives
Cryptococcus neoformans Severe immunosuppression Fluconazole, 2–8 mg/kg po
q.d. (BI)
Itraconazole, 2–5 mg/kg po
q12–24h (CIII)
Histoplasma capsulatum Severe immunosuppression,
endemic geographic area
Itraconazole, 2–5 mg/kg po
q12–24h (CIII)
Fluconazole, 2–8 mg/kg po
q.d. (CIII)
Coccidioides immitis Severe immunosuppression,
endemic geographic area
Fluconazole, 2–8 mg/kg po
q.d. (CIII)
Itraconazole, 2–5 mg/kg po
q12–24h (CIII)
CMV¶ CD4+ count of <50/µL and
CMV antibody positivity




Influenza A virus High risk of exposure (e.g.,
institutional outbreak)
Rimantadine or amantadine,
5 mg/kg q.d. (maximum,
150 mg) in 2 divided doses
po for children <10 y old;
for children ≥10 y old,
5 mg/kg up to 40 kg, then




     NOTE. Not all of the recommended regimens reflect current Food and Drug Administration-approved labeling. b.i.w.
= twice weekly; CMV = cytomegalovirus; IVIG = intravenous immune globulin; q.m. = monthly; t.i.w. = three times weekly;
TMP-SMZ = trimethoprim-sulfamethoxazole; and VZIG = varicella-zoster immune globulin. The Respirgard II nebulizer is
manufactured by Marquest, Englewood, CO. Letters and Roman numerals in parentheses after regimens indicate the
strength of the recommendation and the quality of the evidence supporting it (see text).
 * The efficacy of parenteral pentamidine (e.g., 4 mg/kg q.m.) is controversial. TMP-SMZ and dapsone/pyrimethamine (and
possibly dapsone alone) appear to be protective against toxoplasmosis, although relevant data have not been prospectively
collected. Daily treatment with TMP-SMZ reduces the frequency of some bacterial infections. Patients receiving
sulfadiazine/pyrimethamine for toxoplasmosis are protected against P. carinii pneumonia and do not need TMP-SMZ.
†
Protection against T. gondii is provided by the preferred antipneumocystitis regimens. Dapsone alone cannot be
recommended on the basis of currently available data. Pyrimethamine alone probably provides little, if any, protection.
§
Ketoconazole and fluconazole are preferred for prophylaxis of esophagitis and severe mucocutaneous infection.
¶
Data on oral ganciclovir are still being evaluated; the durability of its effect is unclear. Acyclovir is not protective against
CMV.
** The following immunization schedule for HIV-exposed/infected infants is strongly recommended as the standard of care:
Age (mo) Immunization (dose) Age (mo) Immunization (dose)
Newborn Hep B (1)a
1 Hep B (2)  7 Influenza (1)
e
2 DTP (1), Hib (1)
b   8 Influenza (2)e
3 EIPV (1)
b




4 DTP (2), hIB (2)
b










     NOTE. DTaP = diphtheria and tetanus toxoids with acellular pertussis; DTP = diphtheria-tetanus-pertussis; EIPV = enhanced
inactivated polio vaccine; Hep B = hepatitis B; Hib = Haemophilus influenzae type b; and MMR = measles-mumps-rubella. This
schedule differs from that recommended for immunization of immunocompetent children (20,21 ) in the following ways: (1)
EIPV replaces oral polio vaccine, and the first two doses of EIPV may be given at 3 and 5 months instead of 2 and 4 months;
(2) the second dose of Hep B vaccine is given at 1 month; and (3) pneumococcal vaccine is recommended. This schedule is
designed to deliver vaccine to HIV-infected children as early as possible and to limit the number of injections to two per visit.
a
Infants born to mothers positive for hepatitis B surface antigen should receive hepatitis B immune globulin within 12 hours
of birth in addition to Hep B vaccine (17 ).
b
DTP and Hib vaccines are available together or separately. With the combined DTP-Hib vaccine, a single injection on each
occasion is sufficient and can be given at 2, 4, and 6 months. Administration of EIPV as a second injection at 2 and 4 months
can replace separate immunizations at 3 and 5 months.
c
The need for a third dose of Hib vaccine depends on which formulation was used previously. Regardless of whether the
primary series requires two or three doses, a booster dose is required at 12–15 months.
d
If DTP and Hib are given as separate injections at 6 months, the third dose of Hep B vaccine may be postponed until the next
visit.
e
Primary immunization against influenza for children <9 years of age requires two doses of vaccine, the first of which can be
given as early as 6 months of age (13,18 ). Subsequent vaccination should be undertaken annually, before the influenza season.
f
HIV-infected children should receive prophylactic immunoglobulin after exposure to measles, whether or not they have been
vaccinated against measles.
g
DTaP can be administered at either 15 or 18 months. Alternatively, a fourth dose of DTP can be given as early as 12 months.
h
Some authorities recommend revaccination for HIV-infected children vaccinated ≥6 years previously (13 ).
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TABLE 4B. Prophylaxis for recurrence of opportunistic disease (after chemotherapy
for acute disease) in HIV-infected infants and children
Preventive regimens
Pathogen Indication First choice Alternatives
I. Recommended for life as
standard of care 
Pneumocystis carinii Prior P. carinii pneumonia TMP-SMZ, 150/750 mg/m2/d in
2 divided doses po t.i.w. on
consecutive days (AI);
acceptable alternative
schedules for same dosage
(AI); single dose po t.i.w. on
consecutive days, 2 divided
doses po q.d., or 2 divided
doses po t.i.w. on alternate
days
Aerosolized pentamidine
(children ≥5 y old), 300 mg
q.m. via Respirgard II nebulizer
(AI); dapsone (children ≥1 mo
old), 2 mg/kg (not to exceed
100 mg) po q.d. (CIII); iv
pentamidine (4 mg/kg) every
2–4 w (CIII)
Toxoplasma gondii* Prior toxoplasmic
encephalitis
Sulfadiazine, 85–120 mg/kg in
2–4 divided doses po q.d. plus
pyrimethamine, 1 mg/kg or
15 mg/m2 (maximum, 25 mg)
po q.d., plus leucovorin, 5 mg
po every 3 d (AII)
Clindamycin, 20–30 mg/kg in
4 divided doses po q.d., plus
pyrimethamine, 1 mg/kg po
q.d., plus leucovorin, 5 mg po
every 3 d (AII)
Mycobacterium avium
complex†
Prior disease Clarithromycin, 30 mg/kg in
2 divided doses po q.d., plus at
least one of the following:
ethambutol, 15–25 mg/kg po
q.d.; clofazimine, 50–100 mg
po q.d.; rifabutin, 300 mg po
q.d.; ciprofloxacin, 20–30
mg/kg in 2 divided doses po
q.d. (CIII)
None
Cryptococcus neoformans Documented disease Fluconazole, 2–8 mg/kg po q.d.
(CIII)
Itraconazole, 2–5 mg/kg po
q12–24h (CIII); amphotericin B,
0.5–1.5 mg/kg iv q.w.–t.i.w. (AI)
Histoplasma capsulatum Documented disease Itraconazole, 2–5 mg/kg po
q12–48 h (CIII)
Fluconazole, 2–8 mg/kg po q.d.
(CIII); amphotericin B, 1.0
mg/kg iv q.w. (AI)
Coccidioides immitis Documented disease Fluconazole, 2–8 mg/kg po q.d.
(CIII)
Amphotericin B, 1.0 mg/kg iv
q.w. (AI)
Cytomegalovirus§ Prior end-organ disease Ganciclovir, 10 mg/kg in
2 divided doses iv q.d. for 1 w,
then 5 mg/kg iv q.d.; or





Bacteremia TMP/SMZ, 150/750 mg/m2 in
2 divided doses po q.d. for
several months (CIII)
Ampicillin, 50–100 mg in
4 divided doses po q.d. (CIII);
chloramphenicol, 50–75 mg/kg
in 4 divided doses po q.d. (CIII)
(For children >6 y old, consider
ciprofloxacin, 30 mg in
2 divided doses po q.d. (CIII)
II. Recommended only if
subsequent episodes
are frequent or severe
Invasive bacterial
infections
More than 2 infections in
1-yr period
IVIG, 400 mg/kg q.m. (AI) TMP-SMZ 150/750 mg/m2 po q.d.
(AI)
Herpes simplex virus Frequent/severe
recurrences
Acyclovir, 600–1,000 mg in
3–5 divided doses po q.d. (CIII)
Candida species Frequent/severe
recurrences
Ketoconazole, 5–10 mg/kg po
q12–24h; or fluconazole,
2–8 mg/kg po q.d. (BI)
     NOTE. Not all of the recommended regimens reflect current Food and Drug Administration-approved
labeling. IVIG = intravenous immune globulin; q.m. = monthly; q.w. = weekly; t.i.w. = three times weekly;
and TMP-SMZ = trimethoprim-sulfamethoxazole. The Respirgard II nebulizer is manufactured by Marquest,
Englewood, CO. Letters and Roman numerals in parentheses after regimens indicate the strength of the
recommendation and the quality of the evidence supporting it (see text).
* Only pyrimethamine/sulfadiazine confers protection against P. carinii pneumonia. Although the clindamycin/
pyrimethamine regimen is an alternative for adults, it has not been tested in children. However, these drugs
are safe and are used for other infections.
†
Ciprofloxacin should not be given to children <6 years of age. Rifabutin (5 mg/kg po q.d.) may be given to
children <6 years of age when a suspension becomes available.
§
Oral ganciclovir has not been studied in children.
¶
Choice of drug should be determined by susceptibilities of the organism isolated.
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TABLE 5. Advising patients about the avoidance of exposure to opportunistic
pathogens
Sexual Exposures
(1) Patients should use male latex condoms during every act of sexual intercourse to reduce the risk of expo-
sure to cytomegalovirus, herpes simplex virus, and human papillomavirus, as well as to other sexually
transmitted pathogens (AII). Use of latex condoms will also prevent the transmission of HIV to others.
(2) Patients should avoid sexual practices that may result in oral exposure to feces (e.g., oral-anal contact) to
reduce the risk of intestinal infections such as cryptosporidiosis, shigellosis, campylobacteriosis, amebi-
asis, giardiasis, and hepatitis A and B (BIII).
Environmental and Occupational Exposures
(1) Certain activities or types of employment may increase the risk of exposure to tuberculosis (BIII). These
include volunteer work or employment in health care facilities, correctional institutions, and shelters for the
homeless as well as in other settings identified as high risk by local health authorities. Decisions about
whether or not to continue with such activities should be made in conjunction with the health care provider
and should take into account such factors as the patient’s specific duties in the workplace, the prevalence
of tuberculosis in the community, and the degree to which precautions designed to prevent the transmis-
sion of tuberculosis are taken in the workplace (BIII). These decisions will affect the frequency with which
the patient should be screened for tuberculosis. 
(2) Child-care providers and parents of children in child-care facilities are at increased risk of acquiring CMV
infection, cryptosporidiosis, and other infections (e.g., hepatitis A and giardiasis) from children. The risk of
acquiring infection can be diminished by good hygienic practices, such as hand washing after fecal contact
(e.g., during diaper changing) and after contact with urine or saliva (AII). All children in child-care facilities
are also at increased risk of acquiring these same infections; parents and other caretakers of HIV-infected
children should be advised of this risk (BIII).
(3) Occupations involving contact with animals (e.g., veterinary work and employment in pet stores, farms, or
slaughterhouses) may pose a risk of cryptosporidiosis, toxoplasmosis, salmonellosis, campylobacteriosis,
or bartonella infection. However, the available data are insufficient to justify a recommendation against
work in such settings.
(4) Contact with young farm animals, especially animals with diarrhea, should be avoided to reduce the risk of
cryptosporidiosis (BII).
(5) Hand washing after gardening or other contact with soil may reduce the risk of cryptosporidiosis and
toxoplasmosis (BIII).
(6) In histoplasmosis-endemic areas, patients should avoid activities known to be associated with increased
risk, including cleaning chicken coops, disturbing soil beneath bird-roosting sites, and exploring caves
(CIII).
(7) In coccidioidomycosis-endemic areas, when possible, patients should avoid activities associated with in-
creased risk, including those involving extensive exposure to disturbed soil, as occurs at building
excavation sites, on farms, or during dust storms (CIII).
Pet-Related Exposures
Health care providers should advise HIV-infected persons of the potential risk posed by pet ownership. How-
ever, they should be sensitive to the possible psychological benefits of pet ownership and should not routinely
advise HIV-infected persons to part with their pets (DIII). Specifically, providers should advise HIV-infected pa-
tients of the following.
General
(1) Veterinary care should be sought when a pet develops diarrheal illness. If possible, HIV-infected persons
should avoid contact with animals that have diarrhea (BIII). A fecal sample should be obtained from ani-
mals with diarrhea and examined for Cryptosporidium, Salmonella, and Campylobacter.
(2) When obtaining a new pet, HIV-infected patients should avoid animals <6 months of age, especially those
with diarrhea (BIII). Because the hygienic and sanitary conditions in pet breeding facilities, pet stores, and
animal shelters are highly variable, the patient should exercise caution when obtaining a pet from these
sources. Stray animals should be avoided. Animals <6 months of age, especially those with diarrhea,
should be examined by a veterinarian for Cryptosporidium, Salmonella, and Campylobacter (BIII).
(3) Patients should wash their hands after handling pets (especially before eating) and avoid contact with pets’
feces to reduce the risk of cryptosporidiosis, salmonellosis, and campylobacteriosis (BIII). Hand washing by
HIV-infected children should be supervised. 
Prevention of Exposure Recommendations
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TABLE 5. Advising patients about the avoidance of exposure to opportunistic
pathogens — Continued
Cats
(4) Patients should consider the potential risks of cat ownership because of the risks of toxoplasmosis and
Bartonella infection, as well as enteric infection (CIII). Those who elect to obtain a cat should adopt or 
purchase an animal that is >1 year of age and in good health to reduce the risk of cryptosporidiosis, Bar-
tonella infection, salmonellosis, and campylobacteriosis (BII).
(5) Litter boxes should be cleaned daily, preferably by an HIV-negative, nonpregnant person; if the HIV-infected
patient performs this task, he or she should wash the hands thoroughly afterward to reduce the risk of
toxoplasmosis (BIII).
(6) Also to reduce the risk of toxoplasmosis, cats should be kept indoors, should not be allowed to hunt, and
should not be fed raw or undercooked meat (BIII).
(7) Although declawing is not generally advised, patients should avoid activities that may result in cat
scratches or bites to reduce the risk of Bartonella infection (BII). Patients should also wash sites of cat
scratches or bites promptly (CIII); and should not allow cats to lick open cuts or wounds (BIII).
(8) Care of cats should include flea control, to reduce the risk of Bartonella infection (CIII).
(9) Testing of cats for toxoplasmosis (EII) or Bartonella infection (DII) is not recommended.
Birds
(10)Screening of healthy birds for Cryptococcus neoformans, Mycobacterium avium, or Histoplasma capsula-
tum is not recommended (DIII).
Other
(11)Contact with reptiles (such as snakes, lizards, and turtles) should be avoided to reduce the risk of salmonel-
losis (BIII).
(12)Gloves should be used during the cleaning of aquariums to reduce the risk of infection with Mycobac-
terium marinum (BIII).
(13)Contact with exotic pets, such as nonhuman primates, should be avoided (CIII).
Food- and Water-Related Exposures
(1) Raw or undercooked eggs (including foods that may contain raw eggs, such as some preparations of hol-
landaise sauce, Caesar and certain other salad dressings, and mayonnaise); raw or undercooked poultry,
meat, seafood; and unpasteurized dairy products may contain enteric pathogens. Poultry and meat should
be cooked until no longer pink in the middle (internal temperature, >165° F). Produce should be washed
thoroughly before being eaten (BIII). 
(2) Cross-contamination of foods should be avoided. Uncooked meats should not be allowed to come in con-
tact with other foods; hands, cutting boards, counters, and knives and other utensils should be washed
thoroughly after contact with uncooked foods (BIII).
(3) Although the incidence of listeriosis is low, it is a serious disease that occurs unusually frequently among
HIV-infected persons who are severely immunosuppressed. Some soft cheeses and some ready-to-eat
foods (e.g., hot dogs and cold cuts from delicatessen counters) have been known to cause listeriosis. An
HIV-infected person who is severely immunosuppressed and who wishes to reduce the risk of food-borne
disease can prevent listeriosis by reheating these foods until they are steaming hot before eating them
(CIII).
(4) Patients should not drink water directly from lakes or rivers because of the risk of cryptosporidiosis and
giardiasis. Even accidental ingestion of lake or river water while swimming or engaging in other types of
recreational activities carries this risk (BII).
(5)
During outbreaks or in other situations in which a community “boil-water” advisory is issued, boiling of water
for 1 minute will eliminate the risk of cryptosporidiosis (AI). Use of submicron, personal-use water filters
(home/office types) and/or drinking bottled water* may reduce the risk (CIII). Current data are inadequate to
recommend that all HIV-infected persons boil or otherwise avoid drinking tap water in nonoutbreak settings.
However, persons who wish to take independent action to reduce the risk of waterborne cryptosporidiosis may
choose to take precautions similar to those recommended during outbreaks. Such decisions are best made in
conjunction with the health care provider. Persons who opt for a personal-use filter or bottled water should be
aware of the complexities involved in selecting the appropriate products, the lack of enforceable standards for
destruction or removal of oocytes, the cost of the products, and the difficulty of using these products consis-
tently.
* See section on cryptosporidiosis in disease-specific recommendations for information on personal-use filters
and bottled water.
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Travel-Related Exposures
(1) Travel, particularly to developing countries, may carry significant risks for the exposure of HIV-infected
persons to opportunistic pathogens, especially for patients who are severely immunosuppressed. Consult-
ation with health care providers and/or with experts in travel medicine will help patients plan itineraries
(BIII).
(2) During travel to developing countries, HIV-infected persons are at even higher risk for food- and water-
borne infections than they are in the United States. Foods and beverages—in particular, raw fruits and
vegetables, raw or undercooked seafood or meat, tap water, ice made with tap water, unpasteurized milk
and dairy products, and items purchased from street vendors—may be contaminated (AII). Items that are
generally safe include steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbon-
ated) beverages, hot coffee or tea, beer, wine, and water brought to a rolling boil for 1 minute (AII). 
Treatment of water with iodine or chlorine may not be as effective as boiling but can be used, perhaps in
conjunction with filtration, when boiling is not practical (BIII).
(3) Waterborne infections may result from the swallowing of water during recreational activities. To reduce the
risk of cryptosporidiosis and giardiasis, patients should avoid swallowing water during swimming and
should not swim in water that may be contaminated (e.g., with sewage or animal waste) (BII).
(4) Antimicrobial prophylaxis for traveler’s diarrhea is not recommended routinely for HIV-infected persons
traveling to developing countries (DIII). Such preventive therapy can have adverse effects and can promote
the emergence of drug-resistant organisms. Nonetheless, several studies (none involving an HIV-infected
population) have shown that prophylaxis can reduce the risk of diarrhea among travelers. Under selected
circumstances (e.g., those in which the risk of infection is very high and the period of travel brief), the
provider and patient may may weigh the potential risks and benefits and decide that antibiotic prophylaxis
is warranted (CIII). For those individuals to whom prophylaxis is offered, fluoroquinolones, such as
ciprofloxacin (500 mg q.d.) can be considered (BIII). Trimethoprim-sulfamethoxazole (TMP-SMZ) (one
double-strength tablet daily) has also been shown to be effective, but resistance to this drug is now com-
mon in tropical areas. Persons already taking TMP-SMZ for prophylaxis against Pneumocystis carinii
pneumonia (PCP) may gain some protection against traveler’s diarrhea. For HIV-infected persons who are
not already taking TMP-SMZ, the provider should use caution when prescribing this agent for prophylaxis
of diarrhea because of the high rates of adverse reactions and the possible need for the agent for other
purposes (e.g., PCP prophylaxis) in the future.
(5) All HIV-infected travelers to developing countries should carry with them a sufficient supply of an antimi-
crobial agent to be taken as empirically should diarrhea develop (BIII). One appropriate regimen is 500 mg
of ciprofloxacin b.i.d. for 3–7 days. Alternative antibiotics (e.g., TMP-SMZ) should be considered as empiri-
cal therapy for use by children and pregnant women (CIII). Travelers should consult a physician if their
diarrhea is severe and does not respond to empiric therapy, if their stools contain blood, if fever is accom-
panied by shaking chills, or if dehydration develops. Antiperistaltic agents such as diphenoxylate and
loperamide are used for the treatment of diarrhea; however, they should not be used by patients with high
fever or with blood in the stool, and their use should be discontinued if symptoms persist beyond 48 hours
(AII). These drugs are not recommended for children (DIII).
(6) Travelers should be advised about other preventive measures appropriate for anticipated exposures, such
as chemoprophylaxis for malaria, protection against arthropod vectors, treatment with immune globulin,
and vaccination (AII). They should avoid direct contact of the skin with soil and sand (e.g., by wearing shoes
and protective clothing and using towels on beaches) in areas where fecal contamination of soil is likely
(BIII).
(7) In general, live virus vaccines should be avoided (EII). An exception is measles vaccine, which is recom-
mended for nonimmune persons. Inactivated (killed) poliovirus vaccine should be used instead of oral
(live) poliovirus vaccine. Persons at risk for exposure to typhoid fever should be given inactivated paren-
teral typhoid vaccine instead of the live attenuated preparation. Yellow fever vaccine is a live virus vaccine
with uncertain safety and efficacy in HIV-infected persons. Travelers with asymptomatic HIV infection who
cannot avoid potential exposure to yellow fever should be offered the choice of vaccination. If travel to a
zone with yellow fever is necessary and immunization is not performed, patients should be advised of the
risk, instructed in methods for avoiding the bites of vector mosquitoes, and provided with a vaccination
waiver letter.
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8) In general, killed vaccines (e.g., diphtheria-tetanus, rabies, Japanese encephalitis vaccines) should be used
for HIV-infected persons as they would be used for non-HIV-infected persons anticipating travel (BIII).
Preparation for travel should include a review and updating of routine vaccinations, including diphtheria-
tetanus for adults and all routine immunizations for children. The currently available cholera vaccine is not
recommended for persons following the usual tourist itinerary, even if travel includes countries reporting
cases of cholera (DII).
(9) Travelers should be told about other area-specific risks and instructed in ways to reduce those risks (BIII).
Geographically focal infections that pose a high risk to HIV-infected persons include visceral leishmaniasis
(a protozoan infection transmitted by the sandfly) and several fungal infections (e.g., Penicillium marneffei
infection, coccidioidomycosis, and histoplasmosis). Many tropical and developing areas have high rates of
tuberculosis.
    NOTE. Letters and Roman numerals in parentheses indicate the strength of the recommendation and the
quality of the evidence supporting it (see text).
Vol. 44 / No. RR-8 MMWR 33
References
1. CDC. Estimates of HIV prevalence and projected AIDS cases: summary of a workshop, October
31—November 1, 1989. MMWR 1990;39:110–2, 117–9.
2. CDC. Projections of the number of persons diagnosed with AIDS and the number of immu-
nosuppressed HIV-infected persons—United States, 1992–1994. MMWR 1992;41(No.
RR-18):1–29.
3. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected
with human immunodeficiency virus. MMWR 1989;38(No. S-5):1–9.
4. CDC. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults
and adolescents infected with human immunodeficiency virus. MMWR 1992;41(No. RR-       4):
1–11.
5. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium
avium complex disease in patients infected with the human immunodeficiency virus. N Engl
J Med 1993;329:898–904.
6. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of oppor-
tunistic infections in persons infected with human immunodeficiency virus: Introduction. Clin
Infect Dis 1995;21(suppl 1):1–11.
7. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of oppor-
tunistic infections in persons infected with human immunodeficiency virus: an overview. Clin
Infect Dis 1995;21(suppl 1):12–31. 
8. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines
for the prevention of opportunistic infections in persons infected with human immunodefi-
ciency virus: disease-specific recommendations. Clin Infect Dis 1995;21(suppl 1):32–43.
9. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection.
Clinical practice guidelines no. 7. Rockville, MD: U.S. Department of Health and Human Serv-
ices, 1994; AHCPR publication No. 94-0572.
10. Gross PA, Barrett TL, Dellinger P, et al. Purpose of quality standards for infectious diseases.
Clin Infect Dis 1994;18:421. 
11. CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for
children infected with or perinatally exposed to human immunodeficiency virus. MMWR
1995;44(No. RR-4):1–11.
12. CDC. 1994 revised classification system for human immunodeficiency virus infection in chil-
dren less than 13 years of age. MMWR 1994;43(No. RR-12):1–10.
13. American Academy of Pediatrics. 1994 Red Book: report of the Committee on Infectious Dis-
eases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994:264,
279–80,375,496–7. 
14. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use
of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;
42(No. RR-4):1–18.
15. D2.400 Standards for blood banks and transfusion services. 16th ed. Bethesda, MD: American
Association of Blood Banks, 1994:12.
16. Castro, KG. Tuberculosis as an opportunistic disease in persons infected with human immu-
nodeficiency virus.  Clin Infect Dis 1995;21(suppl 1):S66–S71.
17. CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United
States through universal childhood vaccination. MMWR 1991;40(No. RR-13):1–25.
18. CDC. Prevention and control of influenza: part I, vaccines. MMWR 1994;43(No. RR-9):1–13.
19. CDC. Prevention and control of influenza: part 2, antiviral agents. MMWR 1994;43(No.
RR-15):1–10.
20. CDC. Recommended childhood immunization schedule–-United States, January 1995. MMWR
1995;43:959–60.
21. Hall CB. The recommended childhood immunization schedule of the United States. American
Academy of Pediatrics. Pediatrics 1995;95:135–7.
34 MMWR July 14, 1995
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control
and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis
for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to
lists@list.cdc.gov. The body content should read subscribe mmwr-toc. Electronic copy also is available
from CDC’s World-Wide Web server at http://www.cdc.gov/ or from CDC’s file transfer protocol server at
ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing
Office, Washington, DC 20402; telephone (202) 783-3238.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments.
The reporting week concludes at close of business on Friday; compiled data on a national basis are officially
released to the public on the following Friday. Address inquiries about the MMWR Series, including material
to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta,
GA 30333; telephone (404) 332-4555.
All material in the MMWR Series is in the public domain and may be used and reprinted without
permission; citation as to source, however, is appreciated.
✩U.S. Government Printing Office: 1995-633-175/05083 Region IV
MMWR
